Roivant (ROIV)

Our PAST TOP PICK with ROIV has triggered its stop at $10.50.  To remain disciplined, we recommend covering the position at this time.  This will result in a net investment loss of 9%, when combined with our previous guidance.  

We again reiterate ROIV as a TOP PICK.   The Swiss based biopharma company continues to develop its long pipeline of projects.  It trades at 2x earnings, under 2x book and supports a robust 128% ROE.  We like that cash reserves are growing, while debt is retired.  We continue to recommend a stop-loss at $10.50, looking to achieve $16 -- upside potential of 28%.  Yield 0% 

We reiterate ROIV as a TOP PICK.  The pharma company has continued to increase R&D spending into drugs for treatment such as autoimmune issues respiratory hypertension.  It trades at 2x trailing earnings and 1.6x book value, while supporting a robust return on equity.  We like that cash reserves are growing, while debt is retired.  We recommend maintaining the stop at $10.50, looking to achieve $15.00 -- upside potential of 27%.  Yield 0%  

After announcing positive reports in two important autoimmune drugs, we again reiterate ROIV as a TOP PICK.  It trades at 2x earnings, under 2x book and supports a robust return on equity.  We like that cash reserves are growing, while debt is retired.  We recommend trailing up the stop (from $9:50) to $10.50, looking to achieve $16.00 -- upside potential of 28%.  Yield 0%

As this $9 billion market cap pharma company will join the S&P MidCap 400, we reiterate ROIV as a TOP PICK.  Cash reserves are growing and the company trades at 1.5x book.  We recommend trailing up the stop (from $7.50) to $9.50, looking to achieve $15 -- upside potential of 33%.  Yield 0%    

The pharma company recently received supportive results for its new product which helps bring relief to patients with eye inflammation and pain and can help avoid total blindness -- steroids are presently the primarily treatment currently.   It trades at 2x trailing earnings and 1.4x book value.  The board has approved a $1.2 billion share buyback, which it has ample and growing cash reserves to manage.  Recently reported revenues beat expectations, growing by 118% from the year previous and is expected to grow by 50% p.a. for at least the next five years.  We recommend setting a stop-loss at $7.50, looking to achieve $16.00.  Yield 0%